/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | LYELLyell Immunopharma, |
|---|---|
| Last close | $12.94 |
| Change % | -5.69% |
| Market cap | $302M |
| P/E | — |
| Revenue | $36000 |
| Rev growth (YoY) | -41.0% |
| Net income | $-274448000 |
| Net margin | -762355.6% |
| EPS (diluted) | $-16.06 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -6.56 |
| Beneish M-Score | — |
| Next earnings | 08-06 → 08-16 |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Green = best in the row among the compared names. Educational only — not investment advice.